FDA Regenerative Medicine Advanced Therapy (RMAT) Designations Hit Record High of 48 in 2025, Accounting for 48% of All Designations in Past Two Years

July 19, 2026

PharmaLive USA

Overview

According to a GlobalData report, the number of Regenerative Medicine Advanced Therapy (RMAT) designations granted by the FDA reached a record-breaking 48 in 2025, with designations in 2024 and 2025 collectively accounting for 48% of all RMATs since the program’s inception. This surge indicates a significant expansion of the clinical-stage regenerative medicine pipeline and rapid progression of innovative therapies through regulatory review. RMAT designation is crucial for accelerating market access for treatments for serious conditions, creating new therapeutic opportunities for patients.

In Depth

Key Findings

A recent GlobalData report has revealed that the U.S. Food and Drug Administration (FDA) granted a record-breaking 48 Regenerative Medicine Advanced Therapy (RMAT) designations in 2025. This exceptional figure means that the designations in 2024 and 2025 alone constitute 48% of all RMAT designations awarded since the program’s inception, unequivocally demonstrating the explosive growth in the regenerative medicine sector and the accelerating trend in regulatory approvals.

Technical / Clinical Details

RMAT designation is a special expedited pathway granted to regenerative medicine products (including cell therapies, gene therapies, and tissue-engineered products) intended to treat serious or life-threatening conditions. This designation allows developing companies to benefit from intensive FDA guidance, early and frequent consultations, and priority review, significantly shortening the time to market. Eligible products typically rely on early clinical data showing a clinically meaningful improvement over existing therapies. The surge in designations during 2024 and 2025 strongly corroborates an increasing number of innovative regenerative medicine products entering clinical development.

Background & Context

The RMAT designation program was established in 2017 under the 21st Century Cures Act to expedite the development and approval of regenerative medicine products. Its primary goal is to provide groundbreaking therapies to patients with unmet medical needs more quickly. The unprecedented increase in RMAT designations over the past two years signals the maturation of regenerative medicine technologies and the success of companies’ clinical development strategies. This trend serves as a vital indicator for investors, pharmaceutical companies, and patient communities that regenerative medicine is transitioning from an experimental domain to a mainstream medical field.

Strategic Significance & Outlook

The sustained increase in RMAT designations strongly suggests continued acceleration in the regulatory review and market introduction of regenerative medicine products. This will likely lead to a greater availability of new therapeutic options across a wide range of disease areas, including cancer, rare genetic disorders, cardiovascular diseases, and neurodegenerative conditions. Developing companies will leverage the benefits of RMAT designation to streamline clinical trials and aim for earlier approvals. This dynamic trend forecasts further expansion of the regenerative medicine market, with technological innovation playing a central role in shaping the future of healthcare.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.